PDX Model Features
Clinically Relevant to the Core
Dedication to excellence in translational oncology research is what drives Champions Oncology. It begins with the exacting clinical documentation supporting Champions TumorGraft® models, including cancer type and subtype, stage, grade, histology and harvest site. Confidence in the integrity and accuracy of the data is assured because it is derived from individual patient records. Our 85% overall positive predictive value provides added certainty that your patient-derived xenograft (PDX) model results will predict clinical response in patients.
With several hundred patient tumors and growing, our TumorBank reflects disease characteristics that closely mirror those of clinical trial populations. We can provide large cohorts of PDX models for important indication of interest, such as:
- Rare indications
Beyond choosing the appropriate tumor type, selecting the right PDX model for research with a targeted therapy also depends on the quality and extent of genomic characterization. Champions Oncology ensures the highest quality of extensive genomic tumor characterization through an ongoing program of whole exome and RNA sequencing that is technically meticulous, methodologically rigorous and thoroughly documented.
Forecasting the Future
With the field of immuno-oncology growing rapidly, Champions Oncology has followed suit with our capabilities in immunotherapy. Several studies utilizing humanized PDX models – Champions ImmunoGrafts™ – are currently being piloted by leading global pharma. As the demand continues to grow, we expect to be able to offer a robust, viable solution for immuno-oncology research.